News

Zacks Investment Research on MSN1h
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...
Zepbound beats Wegovy for weight loss in trial of blockbuster drugs
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
STAT1d
Novo Nordisk strikes deal with Septerna to develop obesity pills
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Weight-Loss Drugs Aren’t Really About Weight
The best metric is not weight, but a particularly toxic kind of fat.
Novo Nordisk Strikes $2.2 Billion Deal With Septerna to Develop New Obesity Treatments
COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...
Which Weight-Loss Drug Works the Best?
While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...
Why Weight-Loss Developer Stocks Tumbled on Tuesday
A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...